Just a moment, the page is loading...

EXPAND: (2) Real-world experience with DTG/3TC highlighting the barrier to resistance versus BIC/FTC/TAF (bictegravir/emtricitabine/tenofovir alafenamide)

What is the effectiveness and barrier to resistance of Dovato versus B/F/TAF in populations with conventionally more difficult to treat HIV, including:
  • individuals at risk of non-adherence?

  • People living with HIV with high VL and/or low CD4?

Please refer to the attached documents below for additional guidance related to this RFP and completing the Concept and Proposal forms.

Responses for this RFP may be submitted now through Dec 9, 2022 at 10:00 PM GMT (London) / 5:00 PM EST (New York)

EXPAND RFP Summary.pdf
EXPAND RFP Application Instructions.pdf
EXPAND RFP Concept Template.docx
- Back to Top -